Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis

Overview of attention for article published in Quality of Life Research, August 2003

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (70th percentile)

Mentioned by

policy: 2 policy sources

Readers on

mendeley: 40 Mendeley

Summary Policy documents

So far, Altmetric has seen 2 policy documents that reference this research output.

Riluzole for Amyotrophic Lateral Sclerosis Treatment

Cited by Canadian Agency for Drugs and Technologies in Health on 05 Jul 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Motor neurone disease: assessment and management : Appendices A-Q

Cited by National Institute for Health and Care Excellence on 27 Jan 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.